Prostate cancer metabolite quantification relative to water in 1H-MRSI in vivo at 3 Tesla

Magnetic Resonance in Medicine

Volumn 65, Issue 4, 2011, Pages 914-919

  McLean, Mary A ^a   Barrett, Tristan ^b   Gnanapragasam, Vincent J ^c   Priest, Andrew N ^b,d   Joubert, Ilse ^b   Lomas, David J ^b   Neal, David E ^a,c   Griffiths, John R ^a   Sala, Evis ^b  

^a CANCER RESEARCH UK CAMBRIDGE RESEARCH INSTITUTE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

choline; citrate; magnetic resonance spectroscopy; prostate cancer; quantification

Indexed keywords

BIOMOLECULES; DISEASES; MAGNETIC RESONANCE; MAGNETIC RESONANCE SPECTROSCOPY; MAGNETISM; UROLOGY;

CHOLINE; CITRATE; MAGNETIC RESONANCE SPECTROSCOPIC IMAGING; PHYSIOLOGICAL CONCENTRATIONS; PROSTATE CANCERS; QUALITY CRITERIA; QUANTIFICATION; TREATMENT EFFECTS;

METABOLITES;

CHOLINE; CITRIC ACID; CREATINE; WATER;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALE; PROSTATE CANCER; PROTON NUCLEAR MAGNETIC RESONANCE;

EID: 79952779457     PISSN: 07403194     EISSN: 15222594     Source Type: Journal    
DOI: 10.1002/mrm.22703     Document Type: Article

References (30)

1. Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics. CA Cancer J Clin 2010;60:277-300.
2. Kurhanewicz J, Vigneron DB,. Advances in MR spectroscopy of the prostate. Magn Reson Imaging Clin N Am 2008; 16: 697-710.
3. Zakian KL, Sircar K, Hricak H, Chen HN, Shukla-Dave A, Eberhardt S, Muruganandham M, Ebora L, Kattan MW, Reuter VE, Scardino PT, Koutcher JA,. Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology 2005; 234: 804-814. (Pubitemid 40250824)
4. Mueller-Lisse UG, Swanson MG, Vigneron DB, Hricak H, Bessette A, Males RG, Wood PJ, Noworolski S, Nelson SJ, Barken I, Carroll PR, Kurhanewicz J,. Time-dependent effects of hormone-deprivation therapy on prostate metabolism as detected by combined magnetic resonance imaging and 3D magnetic resonance spectroscopic imaging. Magn Reson Med 2001; 46: 49-57. (Pubitemid 32592138)
5. Mueller-Lisse UG, Swanson MG, Vigneron DB, Kurhanewicz J,. Magnetic resonance spectroscopy in patients with locally confined prostate cancer: association of prostatic citrate and metabolic atrophy with time on hormone deprivation therapy, PSA level, and biopsy Gleason score. Eur Radiol 2007; 17: 371-378. (Pubitemid 46140308)
6. Provencher SW,. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 1993; 30: 672-679. (Pubitemid 23360802)
7. Tran TK, Vigneron DB, Sailasuta N, Tropp J, Le Roux P, Kurhanewicz J, Nelson S, Hurd R,. Very selective suppression pulses for clinical MRSI studies of brain and prostate cancer. Magn Reson Med 2000; 43: 23-33. (Pubitemid 30027109)
8. Schricker AA, Pauly JM, Kurhanewicz J, Swanson MG, Vigneron DB,. Dualband spectral-spatial RF pulses for prostate MR spectroscopic imaging. Magn Reson Med 2001; 46: 1079-1087. (Pubitemid 33104295)
9. Scheenen TWJ, Heijmink SWTPJ, Roell SA, Hulsbergen-Van de Kaa CA, Knipscheer BC, Witjes JA, Barentsz JO, Heerschap A,. Three-dimensional proton MR spectroscopy of human prostate at 3T without endorectal coil: feasibility. Radiology 2007; 245: 507-516. (Pubitemid 47612533)
10. Trabesinger AH, Meier D, Dydak U, Lamerichs R, Boesiger P,. Optimizing PRESS localized citrate detection at 3 Tesla. Magn Reson Med 2005; 54: 51-58. (Pubitemid 40898396)
11. McLean MA, Priest AN, Joubert I, Lomas DJ, Kataoka MJ, Earl H, Crawford R, Brenton J, Griffiths JR, Sala E,. Metabolic characterization of primary and metastatic ovarian cancer by 1H-MRS in vivo at 3 Tesla. Magn Reson Med 2009; 62: 855-861.
12. Wright SM, Wald LL,. Theory and application of array coils in MR spectroscopy. NMR Biomed 1997; 10: 394-410. (Pubitemid 28110735)
13. De Bazelaire CM, Duhamel GD, Rofsky NM, Alsop DC,. MR imaging relaxation times of abdominal and pelvic tissues measured in vivo at 3.0 T: preliminary results. Radiology 2004; 230: 652-659. (Pubitemid 38252858)
14. 2 measurements with cell density in prostate cancer at 3.0 Tesla. Invest Radiol 2009; 44: 572-576.
15. Scheenen TW, Gambarota G, Weiland E, Klomp DW, Futterer JJ, Barentsz JO, Heerschap A,. Optimal timing for in vivo 1H-MR spectroscopic imaging of the human prostate at 3T. Magn Reson Med 2005; 53: 1268-1274. (Pubitemid 40734645)
16. Weinreb JC, Blume JD, Coakley FV, Wheeler TM, Cormack JB, Sotto CK, Cho H, Kawashima A, Tempany-Afdhal CM, Macura KJ, Rosen M, Gerst SR, Kurhanewicz J,. Prostate cancer: sextant localization at MR imaging and MR spectroscopic imaging before prostatectomy-results of ACRIN prospective multi-institutional clinicopathologic study. Radiology 2009; 251: 122-133.
17. Shukla-Dave A, Hricak H, Moskowitz C, Ishill N, Akin O, Kuroiwa K, Spector J, Kumar M, Reuter VE, Koutcher JA, Zakian KL,. Detection of prostate cancer with MR spectroscopic imaging: an expanded paradigm incorporating polyamines. Radiology 2007; 245: 499-506. (Pubitemid 47612532)
18. Cirillo S, Petracchini M, Della Monica P, Gallo T, Tartaglia V, Vestita E, Ferrando U, Regge D,. Value of endorectal MRI and MRS in patients with elevated prostate-specific antigen levels and previous negative biopsies to localize peripheral zone tumours. Clin Radiol 2008; 63: 871-879.
19. Mazaheri Y, Shukla-Dave A, Hricak H, Fine SW, Zhang J, Inurrigarro G, Moskowitz CS, Ishill NM, Reuter VE, Touijer K, Zakain KL, Koutcher JA,. Prostate cancer: identification with combined diffusion-weighted MR imaging and 3D 1H MR spectroscopic imaging-correlation with pathologic findings. Radiology 2008; 246: 480-488.
20. Shukla-Dave A, Hricak H, Ishill N, Moskowitz CS, Drobnjak M, Reuter VE, Zakian KL, Scardino PT, Cordon-Cardo C,. Prediction of prostate cancer recurrence using magnetic resonance imaging and molecular profiles. Clin Cancer Res 2009; 15: 3842-3849.
21. Turkbey B, Pinto PA, Mani H, Bernardo M, Pang Y, McKinney YL, Khurana K, Ravizzini GC, Albert PS, Merino MJ, Choyke PL,. Prostate cancer: value of multiparametric MR imaging at 3 T for detection-histopathologic correlation. Radiology 2010; 255: 89-99.
22. Umbehr M, Bachmann LM, Held U, Kessler TM, Sulser R, Weishaupt D, Kurhanewicz J, Steurer J,. Combined magnetic resonance imaging and magnetic resonance spectroscopy imaging in the diagnosis of prostate cancer: a systematic review and meta-analysis. Eur Urol 2009;55:575-590.
23. Parivar F, Hricak H, Shinohara K, Kurhanewicz J, Vigneron DB, Nelson SJ, Carroll PR,. Detection of locally recurrent prostate cancer after cryosurgery: evaluation by transrectal ultrasound, magnetic resonance imaging, and three-dimensional proton magnetic resonance spectroscopy. Urology 1996; 48: 594-599.
24. Pickett B, Kurhanewicz J, Coakley F, Shinohara K, Fein B, Roach M,. Use of MRI and spectroscopy in evaluationof external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 60: 1047-1055.
25. Dong ZC, Peterson B,. The rapid and automatic combination of proton MRSI data using multi-channel coils without water suppression. Magn Reson Imaging 2007; 25: 1148-1154. (Pubitemid 47464834)
26. Rodgers CT, Robson MD,. Receive array magnetic resonance spectroscopy: whitened singular valued decomposition (WSVD) gives optimal Bayesian solution. Magn Reson Med 2010; 63: 881-891.
27. Lowry M, Liney GP, Turnbull LW, Manton DJ, Blackband SJ, Horsman A,. Quantification of citrate concentration in the prostate by proton magnetic resonance spectroscopy: zonal and age-related differences. Magn Reson Med 1996; 36: 352-358. (Pubitemid 26299260)
28. Futterer JJ, Scheenen TW, Huisman HJ, Klomp DWJ, van Dorsten FA, Hulsbergen-van de Kaa CA, Witjes JA, Heerschap A, Barentsz JO,. Initial experience of 3 Tesla endorectal coil magnetic resonance imaging and 1H-spectroscopic imaging of the prostate. Invest Radiol 2004; 39: 671-680. (Pubitemid 39425960)
29. Cunningham CH, Vigneron DB, Marjanska M, Chen AP, Xu D, Hurd RE, Kurhanewicz J, Garwood M, Pauly JM,. Sequence design for MR spectroscopic imaging of prostate at 3 Tesla. Magn Reson Med 2005; 53: 1033-1039. (Pubitemid 40627778)
30. Liney GP, Turnbull LW, Knowles AJ,. In vivo magnetic resonance spectroscopy and dynamic contrast enhanced imaging of the prostate gland. NMR Biomed 1999; 12: 39-44. (Pubitemid 29135408)